Department of Internal Medicine, Omaha VA Medical Center, Omaha, Nebraska, USA.
J Natl Compr Canc Netw. 2012 Feb;10(2):230-9. doi: 10.6004/jnccn.2012.0021.
Lung cancer is a disease of the elderly, with a median age at diagnosis of 70 years. However, there is a dearth of good quality evidence to guide treatment in this population and most of the data are extrapolated from younger patients. Current research is directed toward establishing simplified instruments to quantify fitness of older patients for various forms of therapy. Although current evidence suggests that outcomes after standard therapy are similar to those seen in younger patients, older patients have an increased incidence of adverse events. Until better predictive markers are available to guide treatment, therapy should be individualized using available instruments, including a comprehensive geriatric assessment. If an older patient is deemed to be fit, it is reasonable to use the treatment options recommended for younger individuals. This article summarizes the available data on the treatment of non-small cell lung cancer in the older patient.
肺癌是一种老年病,诊断时的中位年龄为 70 岁。然而,针对这一人群的治疗缺乏高质量的证据,并且大多数数据都是从年轻患者中推断出来的。目前的研究旨在建立简化的工具,以量化老年患者接受各种治疗形式的健康状况。尽管目前的证据表明,标准治疗后的结果与年轻患者相似,但老年患者发生不良事件的几率更高。在更好的预测标志物可用于指导治疗之前,应使用现有的工具(包括全面的老年评估)对治疗进行个体化。如果认为老年患者健康状况良好,则可以使用推荐给年轻患者的治疗方案。本文总结了现有关于老年非小细胞肺癌治疗的相关数据。